Decoy Therapeutics Inc. (DCOY NASDAQ) stock market data APIs
$6.6478
-0.12(-1.8%)
as of June 5, 2026
Try our APIs with
free plan!
Decoy Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Prev. Close
6.6478
Open
6.5316
High
7.2233
Low
6.355
52 wk Range
4.32-239.4
Market Cap
3 516 K
P/E Ratio
0.0619
Shares Outstanding
532 K
EPS
-4.18
Beta
0.378
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Decoy Therapeutics Inc. data using free add-ons & libraries
Get Decoy Therapeutics Inc. Fundamental Data
Decoy Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -4 649 061
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: -4.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Decoy Therapeutics Inc. News
New
Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch
(RTTNews) - Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyri...
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from th...
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up
(RTTNews) - Decoy Therapeutics, Inc. (DCOY), a preclinical biopharmaceutical company, announced on Tuesday that the development of its peptide-conjugate antiviral platform has reached a Global Access ...
Get Decoy Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
